-       Report 
   - January 2025
    -  175 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - June 2025
    -  400 Pages 
    Global
   
   From       €4448EUR$4,949USD£3,901GBP 
                -       Report 
   - October 2025
    -  1400 Pages 
    Global
   
   From       €4490EUR$4,995USD£3,937GBP 
                -       Report 
   - February 2025
    -  315 Pages 
    Global
   
   From       €4313EUR$4,799USD£3,783GBP 
                -       Report 
   - April 2025
     Global
   
   From       €4404EUR$4,900USD£3,862GBP 
                 -       Report 
   - October 2025
     Global
   
   From       €4404EUR$4,900USD£3,862GBP 
                -       Report 
   - January 2025
    -  100 Pages 
    Global
   
   From       €5348EUR$5,950USD£4,690GBP 
                  -       Report 
   - October 2025
    -  197 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                  -       Report 
   - October 2025
    -  194 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                  -       Report 
   - October 2025
    -  198 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                  -       Report 
   - August 2025
    -  199 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                -       Report 
   - April 2025
    -  200 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - January 2025
    -  175 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - November 2025
    -  224 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
                -       Report 
   - February 2025
    -  185 Pages 
    Global
   
   From       €4045EUR$4,500USD£3,547GBP 
                  -       Report 
   - October 2025
    -  183 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                  -       Report 
   - October 2025
    -  190 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                -       Report 
   - November 2025
    -  139 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
             
         Melanoma is a type of cancer that affects the skin and is the most serious form of skin cancer. It is caused by the uncontrolled growth of pigment-producing cells, known as melanocytes. Melanoma is the fifth most common cancer in the United States, with an estimated 87,110 new cases in 2020. It is also the leading cause of death from skin disease.
The melanoma market within the oncology space is a rapidly growing segment, driven by the increasing prevalence of the disease and the development of new    treatments. The market is expected to be driven by the increasing adoption of targeted therapies, immunotherapies, and combination therapies. Additionally, the increasing focus on personalized medicine and the development of novel drug delivery systems are expected to drive the market.
Some of the key players in the melanoma market include Bristol-Myers Squibb, Merck & Co., Novartis, Roche, Pfizer, and Eli Lilly. Show Less   Read more